Financière de Tubize S.A.
TUB
株式のランク
#2119
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
株価
$217.90
最終同期: 2026-10-20
時価総額
$9.70B
変化（1日）
5.57%
変化（1年）
-19.89%
国
BE
取引 Financière de Tubize S.A. (TUB)
カテゴリー
Healthcare
Financière de Tubize S.A.（TUB）の配当履歴
Financière de Tubize S.A.（証券コード：TUB）は合計で26回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$13.63
配当利回り（TTM）：0.0065
すべての配当の合計（株式分割調整済み）は：$13.63
配当利回り（TTM）：0.0065
2000から2026までのFinancière de Tubize S.A.（TUB）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $0.8945 | 0.00% |
| 2025 | $0.8945 | -7.78% |
| 2024 | $0.97 | 12.79% |
| 2023 | $0.86 | 14.67% |
| 2022 | $0.75 | 10.29% |
| 2021 | $0.68 | 9.68% |
| 2020 | $0.62 | 10.71% |
| 2019 | $0.56 | 3.70% |
| 2018 | $0.54 | 3.85% |
| 2017 | $0.52 | 4.00% |
| 2016 | $0.5 | 4.17% |
| 2015 | $0.48 | 0.00% |
| 2014 | $0.48 | 0.00% |
| 2013 | $0.48 | 0.00% |
| 2012 | $0.48 | 0.00% |
| 2011 | $0.48 | 0.00% |
| 2010 | $0.48 | 0.00% |
| 2009 | $0.48 | 1.42% |
| 2008 | $0.4733 | 2.16% |
| 2007 | $0.4633 | 2.21% |
| 2006 | $0.4533 | 3.02% |
| 2005 | $0.44 | 6.46% |
| 2004 | $0.4133 | 8.76% |
| 2003 | $0.38 | 21.29% |
| 2002 | $0.3133 | 23.69% |
| 2001 | $0.2533 | 35.67% |
| 2000 | $0.1867 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $0.8945 | 0.00% |
| 2025 | $0.8945 | -7.78% |
| 2024 | $0.97 | 12.79% |
| 2023 | $0.86 | 14.67% |
| 2022 | $0.75 | 10.29% |
| 2021 | $0.68 | 9.68% |
| 2020 | $0.62 | 10.71% |
| 2019 | $0.56 | 3.70% |
| 2018 | $0.54 | 3.85% |
| 2017 | $0.52 | 4.00% |
| 2016 | $0.5 | 4.17% |
| 2015 | $0.48 | 0.00% |
| 2014 | $0.48 | 0.00% |
| 2013 | $0.48 | 0.00% |
| 2012 | $0.48 | 0.00% |
| 2011 | $0.48 | 0.00% |
| 2010 | $0.48 | 0.00% |
| 2009 | $0.48 | 1.42% |
| 2008 | $0.4733 | 2.16% |
| 2007 | $0.4633 | 2.21% |
| 2006 | $0.4533 | 3.02% |
| 2005 | $0.44 | -46.78% |
| 2004 | $0.8267 | 8.78% |
| 2003 | $0.76 | 21.27% |
| 2002 | $0.6267 | 23.68% |
| 2001 | $0.5067 | 35.74% |
| 2000 | $0.3733 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
